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Background: Combination therapy with budesonide and formoterol reduces exacerbations of asthma, which are
closely associated with human rhinovirus (RV) infections in both children and adults. These data suggest that
budesonide and formoterol inhibit virus-induced inflammatory responses of airway epithelial cells.
Methods: To test this hypothesis, bronchial epithelial (BE) cells were obtained from airway brushings of 8 subjects
with moderate-to-severe allergic asthma and 9 with neither asthma nor respiratory allergies. Cultured BE cells were
incubated for 24 hours with budesonide (1.77 μM), formoterol (0.1 μM), both, or neither, and then inoculated with
RV-16 (5×106 plaque forming units [PFU]/mL). After 24 hours, viral replication (RV RNA), cytokine secretion (CXCL8,
CXCL10, TNFα, IFN-β, IL-28) and mRNA expression (CXCL8, CXCL10, TNF, IFNB1, IL28A&B) were analyzed.
Results: RV infection induced CXCL10 protein secretion and IFNB1 and IL28 mRNA expression. Drug treatments
significantly inhibited secretion of CXCL10 in mock-infected, but not RV-infected, BE cells, and inhibited secretion of
TNFα under both conditions. Neither budesonide nor formoterol, alone or in combination, significantly affected viral
replication, nor did they inhibit RV-induced upregulation of IFNB1 and IL28 mRNA. Overall, RV replication was
positively related to CXCL10 secretion and induction of IFNB1 and IL28 mRNA, but the positive relationship
between RV RNA and CXCL10 secretion was stronger in normal subjects than in subjects with asthma.
Conclusions: Budesonide and formoterol can inhibit BE cell inflammatory responses in vitro without interfering
with viral replication or production of interferons. These effects could potentially contribute to beneficial effects of
budesonide/formoterol combination therapy in preventing RV-induced asthma exacerbations.
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Infections with human rhinoviruses (RVs) are commonly
associated with increased symptoms and acute exacerba-
tions of asthma that require treatment in the emergency
department or hospitalization. In fact, RV infections are
more often detected during acute exacerbations than
any other respiratory virus [1,2]. This close association
has led to research efforts directed at identifying treat-
ment to prevent RV-induced exacerbations of asthma.
Several medications have shown efficacy for prevention
of asthma exacerbations in general. Combination therapy
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reproduction in any medium, provided the oracting beta agonist (LABA) is particularly effective at
preventing exacerbations [3,4]. Results of clinical studies
also suggest that both ICS and combination medications
prevent exacerbations during the common cold season, and
exacerbations that are associated with symptoms of the
common cold [5,6].
Defining mechanisms of these effects is important to
improving the efficacy of medications that prevent exacer-
bations, and several mechanisms have been proposed.
First, RVs initiate infections by first binding to cell surface
receptors on airway epithelial cells. Notably, ICS can
downregulate in vitro expression of intercellular adhesion
molecule 1 (ICAM-1), which is the cellular receptor for 89
of the 100 canonical RV-A and RV-B types [7,8]; however,
glucocorticoid treatment did not prevent the increased
ICAM-1 expression after experimental RV-16 infectionl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of pro-inflammatory chemokines and cytokines from
infected epithelial cells. These factors include chemoat-
tractants for neutrophils (e.g. CXCL8), mononuclear cells
and T cells (e.g. CXCL10), and cytokines such as TNFα that
can potentiate inflammatory cell functions [10-13]. ICS
can inhibit the RV-induced production of both pro-
inflammatory mediators [14] and type I interferons (e.g.
IFN-α) that have antiviral effects [15]. Clinical studies have
shown evidence of this effect in vivo in that either systemic
or topical corticosteroids were associated with increased
RV replication after experimental inoculation with virus;
however, cold severity was not affected [16].
We hypothesized that the combination of budesonide and
formoterol would inhibit virus-induced inflammatory re-
sponses of primary airway epithelial cells in vitro. To test this
hypothesis, we conducted a series of experiments with bron-
chial epithelial (BE) cells that were obtained from subjects
with or without allergic asthma. As a secondary objective,
we compared viral replication and RV-induced responses in
cells from subjects with and without allergic asthma.
Methods
Study subjects
Primary BE cells were obtained from bronchial brushings
of normal subjects and those with moderate to severeTable 1 Study Subjects
Subject Group Gender Age PC20 (mg/mL)
1 N M 24 20
2 N M 21 20
3 N M 22 50
4 N M 21 50
5 N F 20 50
6 N M 40 50
7 N M 30 50
8 N F 24 50
9 N F 21 16
Mean 36
10 A F 20 4.2
11 A F 20 0.4
12 A M 52 nd
13 A F 36 0.3
14 A M 46 nd
15 A F 24 0.9
16 A M 27 0.3
17 A M 21 0.8
Mean 0.7
Definition of abbreviations: N, normal; A, asthma; nd, not done; PC20, provocative co
volume in one second.
*Change in FEV1 after inhaling 2 puffs of albuterol.allergic asthma (Table 1, n = 17). The subjects with allergic
asthma were treated with inhaled or oral corticosteroids,
and these medications were continued up until the time of
bronchoscopy for reasons of safety. The study protocol
was approved by the University of Wisconsin-Madison
Human Subjects Committee. After obtaining informed
consent, lung function tests and methacholine respon-
siveness were determined as described previously [17].
Skin testing was performed to detect IgE specific for
aeroallergens of local importance in Madison, WI [17].
In the asthma group, all subjects had PC20 <8 mg/mL
or >12% reversibility in FEV1 after bronchodilator, and all
had positive skin tests for aeroallergen-specific IgE. In the
normal group, lung function tests were normal, and there
was no evidence of either bronchial hyperresponsiveness
or allergic sensitization.
Bronchial epithelial cells
BE cells from bronchial brushings were cultured as de-
scribed previously [11,18]. Briefly, the cells were removed
from the brush by scraping and vigorous agitation in
Dulbecco's Modified Eagle Medium: Nutrient Mixture
F-12 (DMEM/F12, Life Technologies, Grand Island, NY),
and then placed in tissue culture in collagen coated
plasticware at 37°C (5% CO2) in Bronchial Epithelial




















ncentration of methacholine causing a 20% fall in FEV1; FEV1, forced expiratory
Table 2 Real-time PCR primers used for mRNA
quantification





PPIA-r† CATGCCTTCTTTCACTTTGCC 21 71
IFNB1-f AGGACGCCGCATTGACC 17
IFNB1-r ATTCCAGCCAGTGCTAGATGA 21 83
IL28-f GCTGACCGTGACTGGAGCA 19
IL28-r GACAGGGACTTGAACTGGGCTA 22 93
TNF-f TCGGCCCGACTATCTCGAC 19
TNF-r GCGTTTGGGAAGGTTGGAT 19 94
CXCL10-f AAGCTCTACTGAGGTGCTATGTT 23
CXCL10-r TGGGAAAGGTGAGGGAAATA 20 72
CXCL8-f CAGTTTTGCCAAGGAGTGCTAA 22
CXCL8-r GGTGGAAAGGTTTGGAGTATGTC 23 69
Definition of abbreviations: f, forward primer; r, reverse primer; bp, base pairs.
†The PPIA primer sequences were published by RTPrimerDB, ID #3460
(http://medgen.ugent.be/rtprimerdb/).
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(passage 1), and finally seeded in 12-well plates (passage 2).
Purified and concentrated RV-16 [19] was diluted in
BEGM with a reduced concentration (10-8 M) of hydro-
cortisone (low Hc BEGM) just before infection. Stock
solutions of budesonide (anhydrous) and formoterol
fumarate (dihydrate) were prepared in DMSO at a con-
centration of 10 mM, subsequent dilutions were made
in low Hc BEGM (final concentration of DMSO applied
to cells was ≤ 0.01%). When the cell monolayers (duplicate
wells) from each study subject (passage 2) were app-
roximately 70-80% confluent, they were pre-treated for
24 h with budesonide (1.77 μM), formoterol (0.1 μM),
both (at recommended therapeutic ratio of 17.7:1), or nei-
ther (0.01% DMSO drug vehicle), and then either infected
with 0.25 mL of RV-16 (5×106 plaque forming units
[PFU]/mL), or mock-infected with medium alone for 2 h
at 34°C. Cell monolayers were then washed three times
with PBS before adding fresh low Hc BEGM. After 24 h
incubation at 34°C (5% CO2), cell supernatants were col-
lected, the monolayers were washed with phosphate buff-
ered saline and lysed by adding TRIzol Reagent
(Invitrogen, Carlsbad, CA). Supernatant and cell lysate
samples were stored in microcentrifuge tubes at −80°C
until RNA extraction and cytokine analysis.
Virology
The major receptor group RV-16 was chosen for this
study because major group viruses replicate well in cul-
tured BE cells without causing marked cytopathic ef-
fects [11], and thus is a good model of in vivo infections
[20]. Stocks of virus were grown in HeLa cells and puri-
fied by sucrose gradient centrifugation as described
previously [21].Measurement of viral and cellular RNAs
Total RNA was isolated from the frozen TRIzol lysates
according to manufacturer’s protocol, treated with RQ1
DNase (Promega, WI, USA) and then purified by the
RNeasy Mini Kit (Qiagen, Hilden, Germany). First-strand
cDNA synthesis was performed using the TaqMan Reverse
Transcription reagents and random hexamers (Life Tech-
nologies, Grand Island, NY). PCR was performed as previ-
ously described [18] using the primers shown in Table 2.
Power SYBR Green PCR master mix (Life Technologies)
was used to perform the reactions. Fold differences
were determined by the 2–ΔΔCt method. The cycle thre-
shold (Ct) of each transcript was normalized to the Ct
of the house-keeping gene peptidylprolyl isomerase A
(PPIA) [22]. IL28 primers detect both IL28A and IL28B
mRNAs due to their high sequence identity. We used
RV primers and probe as described previously [20].
A standard curve was derived from purified RV-16 prepof known infectivity, and results are reported in PFU
equivalents (PFUe).
Measurement of cytokine proteins
CXCL8, CXCL10, TNFα and IL-28 concentrations were
assessed using human Cytokine / Chemokine Milliplex
map kits (Millipore, Temecula, CA) according to the
manufacturer’s instructions. Luminex® 100 instrument
(Luminex Corporation, Austin, TX) was used to run
plates and generate quantitative data. Sensitivity of the
assays (minimum detectable concentration) was 0.3 pg/
mL (CXCL8), 2.2 pg/mL (CXCL10), 7.9 pg/mL (IL-28)
and 0.1 pg/mL (TNFα). IFN-β secretion was determined
by ELISA (R&D Systems, Minneapolis, MN) according
to the manufacturer’s instructions. The lower limit of
IFN-β detection was 50 pg/mL.
Data analysis
Mixed-effects ANOVA models were used for all analyses
to account for repeated measures in subjects. All
responses were log-transformed for analysis except
CXCL8 protein. Means and confidence intervals (CIs) of
log-transformed responses were back-transformed and
reported on the original scale of measurement. In the
absence of significant interaction effects, the main effects
for asthma status, RV versus mock treatment, and drug,
are reported. Associations between viral RNA and cyto-
kine mRNA and protein levels were tested in linear
models of CXCL10 with RV, asthma, and RV × asthma
interaction as covariates. Pearson correlation coefficients
were calculated for relationships between RV and cyto-
kine mRNA and protein. P values < 0.05 were consid-
ered statistically significant.
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Viral replication
Measurements were performed in cell lysates (RV RNA,
cytokine mRNA) and supernatants (cytokine protein) col-
lected 24 h post inoculation. When all subjects (n = 17)
were considered together, the geometric mean of RV-16
RNA was 5.3 × 106 (3.2 × 106, 8.8 × 106, 95% CI) PFUe
per sample in the absence of drug treatment (Figure 1A).
Treatment with budesonide and/or formoterol had no ef-
fect on RV replication (Figure 1A, p = 0.43). We next ex-
amined effects of allergic asthma on viral replication and
induction of cytokines in ANOVA models including
subject, asthma status, and drug treatment group. Overall,
viral replication tended to be greater in cells from normal
subjects compared to cells from subjects with asthma
(7.6 ×106 [4.1 × 106, 14.2 × 106] vs. 3.3 × 106 [1.7 × 106,
3.3 × 106] PFUe, p = 0.06; Figure 1B).Drug effects on cytokine induction
RV-16 infection significantly induced secretion of CXCL10
(44 [7.0, 249] vs. 7.2 [5.3, 9.8] pg/mL geometric means
[95% CI], p < 0.001), but not TNFα or CXCL8 (Figure 2).
We also tested for IL-28 and IFN-β secretion, but these
cytokines were not detectable in most samples, and we
therefore analyzed IL28 and IFNB1 mRNA expression by
qPCR. Compared to mock-infected cells and in the ab-
sence of drug treatment, RV induced small amounts of
IFNB1 mRNA (2.2 [1.4, 2.2] fold increase) and larger
amounts of IL28 mRNA (32.2 [14.1, 73.6] fold increase)
(Figure 3), but did not induce TNF or CXCL8 mRNA
(data not shown).
In mock-infected cells, treatment with budesonide,
formoterol, and the combination of both drugs signifi-
cantly inhibited secretion of CXCL10 and TNFα com-
pared to cells without drug treatment (Table 3). None of
the drug treatments had significant effects on CXCL8 se-
cretion in mock-infected cells.Figure 1 Viral replication in BE cells from normal and asthmatic subje
inoculated with RV-16 after 24 h pre-treatment with budesonide (B), formo
viral RNA was measured 24 h post-inoculation. Neither B, F, nor the combin
samples grouped according to asthma status (B). Data are represented as gIn RV-infected samples, treatment with both drugs alone
and the combination inhibited secretion of TNFα, but ef-
fects on CXCL10 were not significant (Table 3). Treatment
with either budesonide or the combination of budesonide
and formoterol also inhibited CXCL8 secretion after RV in-
fection. There were no significant treatment effects of
budesonide, formoterol, or the combination on RV-induced
IFNB1 or IL28 mRNAs (p = 0.27 and 0.14 respectively,
Table 3).
Asthma effects on cytokine induction
Asthma appeared to modify RV-induced secretion of
CXCL10 and TNFα (Table 4) in that RV infection stimu-
lated increased secretion of these cytokines only in sub-
jects without asthma (asthma × RV interaction p values:
CXCL10, 0.003; TNFα, 0.0003). Similarly, asthma was
associated with lower fold increases in RV-induced
IFNB1 mRNA (p = 0.01) and IL28 mRNA (p = 0.009).
There were no effects of asthma on secretion of CXCL8
(data not shown).
Given the trend for less viral replication in the samples
from subjects with asthma, we conducted a post hoc
analysis to determine whether asthma status affected RV
induction of cytokine protein and mRNA. Overall, there
was a positive correlation between RV RNA levels and
induction of both IFNB1 mRNA (r = 0.69, p < 0.001)
and IL28 mRNA (r = 0.71, p < 0.001), and this relation-
ship was not affected by asthma status (Figures 4A and
4B; interaction terms p = 0.36 for IFNB1 and p = 0.54
for IL28). In contrast, there was a positive correlation
between RV RNA level and CXCL10 secretion in cells
from normal individuals (r = 0.36, p = 0.01), but not in
cells from subjects with asthma (r = 0.17, p = 0.48; inter-
action term p=0.07; Figure 4C). For example, a 10-fold
increase in RV RNA was associated with a 11-fold in-
crease (95% CI 1.9, 70) in CXCL10 secretion in the nor-
mal group, compared to only a 1.5 fold increase (95% CI
0.49, 4.6) in the asthma group.cts was not affected by budesonide or formoterol. Cells were
terol (F), both drugs (B+F), or media alone (none) and cell-associated
ation significantly affected RV replication in all samples (A), nor in
eometric means with 95% confidence intervals.
Figure 2 Effects of RV infection and drug treatments on
cytokine protein secretion by BE cells from normal and
asthmatic subjects. Cells were inoculated with RV-16 after 24 h
pre-treatment with budesonide (B), formoterol (F), the combination
(B+F) or media alone (none), and samples of tissue culture medium
obtained 24 h post inoculation were tested for cytokines. Data are
represented as geometric (CXCL10, TNFα) or arithmetic (CXCL8)
means with 95% confidence intervals.
Figure 3 Treatment effects on expression of interferon mRNA
by BE cells from normal and asthmatic subjects. Cells were
inoculated with RV-16 after 24 h pre-treatment with budesonide (B),
formoterol (F), the combination (B+F) or media alone (none) and
then type I (IFNB1) and III (IL28) interferon mRNA levels were
measured by qPCR in cell lysates 24 h post inoculation. Data are
represented as geometric mean fold change compared to
mock-infected cells with 95% confidence intervals.
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measurement of protein vs. mRNA, we also compared
RV RNA to induction of CXCL10 mRNA. RV RNA was
positively correlated with CXCL10 mRNA in both
groups (no asthma r = 0.61, p < 0.0001; asthma r = 0.57,
p < 0.0001), but the slope was significantly greater in
the no asthma group (interaction term p = 0.0008;
Figure 4D). In this case, a 10-fold increase in RV RNA
was associated with a 56-fold increase (95% CI 14, 230)
in CXCL10 mRNA in the normal group, compared to a
2.8-fold increase (95% CI 1.2, 6.8) in CXCL10 mRNA in
the asthma group.Discussion
In addition to serving as host cells for viral infections, air-
way epithelial cells are important initiators of the local
antiviral immune response through the production of
chemokines, pro-inflammatory cytokines, and interferons
[23]. These studies were conducted to determine the ef-
fects of budesonide, formoterol and the combination of
these two drugs on RV-induced cytokine responses of cul-
tured primary BE cells. Because primary cells obtained by
bronchoscopy are usually low in number and have limited
growth potential, we have used high but still clinically rele-
vant concentration of drugs that had shown strong inhibi-
tory effects in vitro [24-26] instead of testing multiple
drug concentrations. The results show that RV infection
stimulated CXCL10 secretion and an antiviral response as
indicated by induction of IFNB1 and IL28 mRNA. Secre-
tion of CXCL10 was significantly inhibited by budesonide,
formoterol and their combination in mock-infected cells,
but none of the treatments significantly affected RV-16-in-
duced CXCL10 secretion. Notably, budesonide, formoterol
or their combination did not significantly affect antiviral
responses as measured by IFNB1 and IL28 mRNA
Table 3 Effects of drugs on cytokine secretion by BE cells from all subjects (mean†, 95% CI, n = 17)
Mock-infected Drugs
None Budesonide Formoterol Both
CXCL8 3940 (3454, 4426) 3546 (2935, 4157) 4279 (3901, 4657) 3780 (3292, 4268)
CXCL10 7.2 (5.3, 9.8) 2.7 (1.6, 4.6)** 3.8 (2.4, 6.1)** 3.3 (1.8, 5.8)**
TNFα 6.7 (3.9, 11) 0.5 (0.2, 1.4)** 2.4 (0.7, 7.8)* 0.8 (0.2, 2.6)**
RV-infected
CXCL8 4163 (3540, 4786) 3504 (2993, 4015)** 4116 (3675, 4557) 3634 (3164, 4104)*
CXCL10 44 (7.0, 249) 29 (9.8, 84) 34 (11, 112) 34 (12, 99)
TNFα 8.1 (4.7, 14) 1.5 (0.5, 4.6)** 2.7 (0.8, 9.2)** 1.3 (0.4, 4.4)**
IFNBI mRNA 2.2 (1.4, 3.2) 2.0 (1.2, 3.8) 2.8 (1.8, 4.3) 2.6 (1.7, 4.0)
IL28 mRNA 32 (14, 74) 19 (8.9, 42) 24 (9.4, 61) 17 (6.7, 42)
†CXCL8 arithmetic mean, others represent geometric means; cytokine protein values represent pg/mL, and mRNA are presented as fold increase after RV infection.
* P ≤ 0.05 drug vs. no drug.
** P ≤ 0.005 drug vs. no drug.
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tion. In contrast, treatment with these drugs inhibited
TNFα secretion with or without infection, and budesonide
or combination of budesonide and formoterol inhibited
CXCL8 secretion after infection. When considered to-
gether, these findings suggest that budesonide and
formoterol hinder BE cell secretion of specific pro-
inflammatory cytokines without affecting epithelial anti-
viral responses.
Another goal of these studies was to test for allergic
asthma effects on epithelial cell immune responses to
RV. In cells from normal individuals, RV infection in-
duced secretion of CXCL10 and TNFα; these responses
were significantly blunted in the asthma group. Further-
more, although levels of interferon protein secretion
were undetectable in most cultures, viral infection con-
sistently upregulated IFNB1 and IL28 mRNA, and these
responses were also lower in the asthma group. Some
[27,28], but not all [17,18,29], previous studies haveTable 4 Effects of asthma status on baseline (Mock) and
RV-induced cytokine secretion and interferon mRNA
expression (geometric mean, 95% CI)




Mock 3.4 (2.2, 5.1) 5.3 (3.5, 8.2) 0.06
RV 50.6 (21.6, 118.1)** 10.1 (4.2, 24.4) 0.003
TNFα
(pg/mL)
Mock 3.2 (1.3, 7.9) 1.4 (0.6, 3.5) 0.02
RV 4.7 (1.9, 11.3)* 1.4 (0,6, 3.5) 0.0003
IFNB1 mRNA
(fold increase)
3.4 (2.2, 5.3) 1.5 (1.0, 2.5) 0.01
IL28 mRNA
(fold increase)
49 (21, 112) 9.2 (3.8, 22) 0.009
*P = 0.006, ** P < 0.0001 for RV vs. mock-infected samples.suggested that epithelial cell interferon responses are
lower in BE cells from subjects with asthma, and these
low interferon responses were inversely related to viral
replication. In contrast, interferon responses were posi-
tively related to viral replication in our study, and the
lower interferon responses observed in the asthma group
were associated with a trend for lower viral replication.
Although the reason for lower replication in the asthma
group is unclear, we speculate that use of inhaled or oral
corticosteroids by the subjects with asthma could have
suppressed ICAM-1 expression, and that this suppres-
sion may have persisted through several cell generations
in tissue culture. Interestingly, post hoc analyses suggest
that allergic asthma status also affected the relationship
between viral replication and induction of CXCL10, a
chemokine for Th1 cells and mononuclear cells that is
strongly induced by RV infection both in vitro and
in vivo [10,17,30]. In our study, the positive correlation
between RV RNA and CXCL10 mRNA and protein was
blunted in subjects with allergic asthma (Figure 4C
and 4D). Additional studies are warranted to determine
whether this effect is also present in vivo.
Budesonide and formoterol combination therapy has
been used extensively in the treatment of asthma, and
controls daily symptoms as well as reducing the risk for
asthma exacerbations [4]. The fact that most asthma ex-
acerbations in children and about half of those in adults
have viral infection as a contributing factor [31] suggests
that combination therapy may specifically inhibit virus-
induced exacerbations. Our findings as well as some pre-
viously published in vitro results [24,25] suggest that
budesonide and formoterol-mediated reduction of BE
cell inflammatory responses may contribute to this ef-
fect. Skevaki et al. [25] have shown that the combination
of budesonide and formoterol administered post infec-
tion suppressed RV-induced pro-inflammatory cytokines
Figure 4 Correlations between RV RNA levels and cytokine responses in BE cells. RV RNA 24 h after inoculation was positively associated
with IFNB1 mRNA (A), IL28 mRNA (B), and CXCL10 cytokine secretion (C) and mRNA upregulation (D). Samples include untreated samples and
also those treated with budesonide, formoterol, and the combination. Results from samples in the normal and asthma groups are indicated by
squares and circles, respectively, and separate regression lines (solid line, normal; dotted line, asthma) are plotted for each group.
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associated growth factor (VEGF) in BE cells in a syner-
gistic or additive manner. In our experimental model,
pre-treatment with budesonide alone or in combination
with formoterol also inhibited pro-inflammatory cyto-
kines (CXCL10, TNFα and CXCL8) at baseline and/or
after RV infection. Synergistic or additive suppression
of RV-induced chemokines was also observed after
pre-treatment of cultured BE cells with fluticasone pro-
pionate and salmeterol [14]. In RV-stimulated peri-
pheral blood mononuclear cells, the combination of
budesonide and formoterol inhibited CXCL10 and also
antiviral responses (IFN-α secretion and expression of
the type I interferon inducible genes) [15]. In contrast,
we did not observe significant inhibitory effects of the
drugs on RV-induced upregulation of CXCL10 secretion
or type I and III interferon genes (e.g. IFNB1 and IL28)
in primary BE cells. Interestingly, RV-16 infection has
been shown to reduce glucocorticoid sensitivity of
airway epithelial cells in vitro through activation ofc-Jun N-terminal kinase (JNK) and nuclear factor κB
(NF-κB) signaling pathways; however, potential effects
of combined treatment with beta agonists have not been
studied [32].
This study has several strengths, and some limita-
tions, that should be considered in interpreting these
results. Strengths of the study include the use of pri-
mary cultures of BE cells, as well as including cells from
donors who were characterized for allergy and asthma.
The donors had moderate or severe allergic asthma with
well-characterized abnormalities in lung function. Fur-
thermore, we used highly purified preparations of RV-
16, as well as sensitive and specific viral diagnostics
(real-time RT-PCR) for these studies. One limitation of
the study is that the asthma and no asthma groups also
differed in allergic status, and so some of the differences
attributed to asthma could be mediated by allergy. In
addition, each of the subjects with asthma was treated
with inhaled or oral corticosteroids, and these medica-
tions were continued up until the time of bronchoscopy
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oid preparations may have been partially washed out
under the conditions in tissue culture, pre-study treat-
ment could have influenced findings in vitro. These
in vitro studies enabled us to isolate responses of BE
cells to virus and drugs, however, it is obvious that epi-
thelial cell responses to viral infection as well as viral
clearance are affected by other cells and cytokines in the
airway milieu [33,34], and correlation with clinical find-
ings is needed to establish relevance in vivo. It has been
shown that the proportion of RV-16-infectible airway
epithelial cells is relatively low (less 10%) in both mono-
layer cultures and bronchial tissue samples infected
ex vivo primarily due to a low basal expression of
ICAM-1, the receptor for RV-16 and other major group
viruses [35]. Therefore, the modest magnitude of virus-
specific cytokine induction in these experiments was
likely due to restriction of infection to the small subset
of BE cells that express ICAM-1.
Conclusions
In summary, these findings indicate that budesonide and
formoterol can inhibit inflammatory responses in vitro in
primary BE cells without affecting viral replication or inter-
fering with induction of the antiviral genes IFNB1 and
IL28. These effects could potentially contribute to bene-
ficial effects of budesonide and budesonide/formoterol
combination therapy in preventing RV-induced asthma ex-
acerbations in vivo. Furthermore, our results raise add-
itional questions about the etiology and potential clinical
significance of asthma-related differences in BE cell re-
sponses to RV infection.
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